BioMedNewsBreaks

WednesdayMay 04, 2022 3:14 pm

BioMedNewsBreaks – IBN’s BioMedWire to Raise Visibility of 2nd Annual Gene Therapy Patient Engagement Summit

IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including BioMedWire (“BMW”), today announced that it will be collaborating with Hanson Wade as an official media sponsor for the upcoming 2nd Annual Gene Therapy Patient Engagement Summit. The event is slated to take place from June 7-9, 2022, in Boston, Massachusetts, and unite patient advocacy groups, engagement leaders and the patients themselves to provide insight and honest discussions. During the three-day summit, presentations will be held on a variety of topics, including managing expectations of gene therapy across stakeholders, incorporating the latest regulatory guidelines on patient…

Continue Reading

WednesdayMay 04, 2022 1:25 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. The piece details InMed Pharmaceuticals and its continued “transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future,” the report reads. “INM also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II…

Continue Reading

TuesdayMay 03, 2022 12:11 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Launch of Physician-Focused Ads as Part of Large-Scale Campaign Around sugarBEAT(R)

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its U.K. licensee, MySugarWatch, as part of a large scale awareness campaign for the company’s sugarBEAT non-invasive continuous glucose monitor, has launched a series of ads in one the U.K.’s preeminent physician and pharmacist education resources, MIMS. “We are very pleased to see our U.K. licensee taking significant steps toward supporting the commercialization efforts around sugarBEAT,” said Nemaura’s CEO Faz Chowdhury, Ph.D. “We are committed to supporting MySugarWatch to ensure the success…

Continue Reading

ThursdayApr 28, 2022 2:41 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated process, Cybin is combining controllable drug-delivery systems with novel psychedelic molecules, thus creating patent-protected, commercially scalable drug candidates. “The company currently is moving three of these drug candidates forward: CYB003, CYB004 and CYB005. Cybin’s active drug programs target major depressive disorder (CYB003), alcohol use disorder (CYB003), anxiety disorders (CYB004) and neuroinflammation (CYB005),” reads a recent article. “Cybin recently announced that it commenced a…

Continue Reading

ThursdayApr 28, 2022 1:35 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced its receipt of approval from the Spanish Agency for Medicines and Health Products (“AEMPS”) Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for CNSP’s potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “We continue to build momentum in our potentially pivotal study of Berubicin, and importantly advance toward bringing…

Continue Reading

ThursdayApr 28, 2022 12:47 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Patent Portfolio with Novel Cannabinoid Analogs, Initiates Strategic Research Collaboration Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the publication of a patent application in North America. The application has broad claims directed to the molecular structure, uses and methods of manufacturing of several cannabinoid analogs. Describing several new cannabinoid-related chemical compounds, the broad patent application, if granted, allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (“NCEs”). “We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs,” said Eric Hsu, SVP,…

Continue Reading

WednesdayApr 27, 2022 1:58 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Focusing on Largely Underserved Indications

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns with Silo Pharma’s mission of identifying assets to license while funding transformative research for the well-being of patients and the health care industry. Silo Pharma focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare…

Continue Reading

TuesdayApr 26, 2022 1:16 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Names New CFO, Corporate Secretary

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced the appointment of a new chief financial officer and corporate secretary. The company named François C. Desrosiers, B. Com (Spec.) and FCSI, as Rryah CFO and corporate; the appointment is subject to approval  by the Canadian Securities Exchange (“CSE”). Desrosiers brings impressive experience in senior executive leadership roles to his new role with RYAH. He has served as cofounder, president, CEO and director at Northcore Resources Inc.; corporate secretary and officer…

Continue Reading

MondayApr 25, 2022 12:45 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Planet MicroCap Showcase 2022

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that it will be presenting at the Planet MicroCap Showcase 2022, which is slated to take place from May 3-5, 2022, at the Bally’s Hotel & Casino in Las Vegas, Nevada. Nemaura’s Dr. Faz Chowdhury will present virtually at the event, with his presentation scheduled to begin at 9 a.m. PT on Wednesday, May 4. Interested parties should visit https://ibn.fm/5QyWV and https://ibn.fm/9wFBj to register for the event, book one-on-one meetings and access Nemaura’s presentation. To view the full press…

Continue Reading

FridayApr 22, 2022 1:26 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers

CNS Pharmaceuticals (NASDAQ: CNSP) is leading the charge toward advancing research on the treatment for glioblastoma multiforme (“GBM”) as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of its lead product candidate, Berubicin, for the treatment of GBM, dosing its first patients in September. A recent article discussing this reads, “CNS Pharmaceuticals expects to report an interim analysis of the trial when 30-50% of the planned subjects reach six months in-study, potentially in the first half of 2023. The adaptive, multicenter, open-label, randomized, and controlled study will involve…

Continue Reading